A phase 2, randomized, placebo-controlled study evaluating matrix metalloproteinase-9 inhibitor, andecaliximab, in patients with moderately to severely active Crohn's disease

Stefan Schreiber, Corey A. Siegel, Keith A. Friedenberg, Ziad H. Younes, Ursula Seidler, Bal R. Bhandari, Ke Wang, Emily Wendt, Matt McKevitt, Sally Zhao, John S. Sundy, Scott D. Lee, Edward V. Loftus

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 2, randomized, placebo-controlled study evaluating matrix metalloproteinase-9 inhibitor, andecaliximab, in patients with moderately to severely active Crohn's disease'. Together they form a unique fingerprint.

Medicine & Life Sciences